Centre National De La Recherche Scientifique-cnrs

Inserm (institut National De La Sante Et De La Recherche Medicale)

Institut De Recherche Pour Le Developpement (ird)

Université De La Réunion Saint Denis

Centre National De La Recherche Scientifique

Institut De Recherche Pour Le Developpement

Inserm

Patrick Mavingui

Philippe Despres

Gilles Gadea

Wildriss Viranaicken

The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.

Vaccine compositions comprising an attenuated mutant Zika virus

Growing community of inventors

Sainte Clotilde la Reunion, France

Patrick Mavingui